Arabic Arabic English English French French German German
dark

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

HUTCHMED Limited announces the first commercial sale in China of ORPATHYS®, HUTCHMED’s oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

“This Is a Scandal”: Documents Reveal Obama’s EPA Approved Toxic Chemicals for Fracking in 2011

Next Post

Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development

Related Posts
Total
0
Share